Abstract: Provided is a magnetic separation device comprising a container having one or more outer surfaces; at least one magnetic sheet; and a physical coupler that is used to detachably secure the container to the magnetic sheet.
Type:
Grant
Filed:
February 1, 1999
Date of Patent:
October 3, 2000
Assignee:
BioCrystal Ltd.
Inventors:
Emilio Barbera-Guillem, Marlin O. Thurston
Abstract: Provided are compositions comprising water-soluble, functionalized nanocrystals. The water-soluble functionalized nanocrystals comprise quantum dots capped with a layer of a capping compound, and further comprise, by operably linking and in a successive manner, one or more additional compounds. The one or more additional compounds is comprised of at least a diaminocarboxylic acid which is operatively linked to the capping compound, and may further comprise an amino acid, an affinity ligand, or a combination thereof. Also provided are methods of using the functionalized nanocrystals having an affinity ligand to detect the presence or absence of a target substrate in a sample.
Type:
Grant
Filed:
August 11, 1999
Date of Patent:
September 5, 2000
Assignee:
BioCrystal Ltd.
Inventors:
Stephanie L. Castro, Emilio Barbera-Guillem
Abstract: Provided is a magnetic separation device comprising a container having one or more outer surfaces; at least one flexible magnetic sheet; and a non-permanent adhesive that is used to detachably secure an outer surface of the container to a flexible magnetic sheet.
Abstract: Provided for use in site-directed chemotherapy are compositions comprising chemotherapeutic agents targeted to either arrested metastatic cells via a cell-surface marker associated with metastasis; or are targeted to type 1 endothelial cells of the tissue comprising the organ site at which metastatic cells arrest such that (a) any arrested metastatic tumor cells are then exposed to the chemotherapeutic agent, and/or (b) the endothelial cells are altered thereby inhibiting the ability of the metastatic tumor cells to arrest, survive or proliferate in that site. Also provided are methods of site-directed chemotherapy of metastatic cells of non-lymphoid tumor origin. Site-directed chemotherapy comprises introducing a therapeutically effective amount of a chemotherapeutic agent directly into a vascular access of the organ having, or suspected of having, arrested metastatic cells thereby concentrating the therapy in the prometastatic territories of the treated organ.